Skip to main content
SpringerLink
Log in

Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

The effect of mitomycin C administration on the generation of cytotoxic cells, induced by in vitro activation of peripheral blood mononuclear cells (PBM) with interleukin-2, was studied in patients with various carcinomas. The ability of PBM to generate lymphokine-activated killer (LAK) cell activity against Raji cell targets was significantly augmented 5 and 7 days after a single intravenous dose of 12 mg/m2 mitomycin C, when compared to that of PBM obtained before mitomycin C injection. Further, LAK cell activity against autologous tumor cells was also significantly increased after the drug administration. The distribution of lymphocyte subsets exhibited a significant increase in the percentage of CD3+ cells after injection, with the elevation of the CD4/CD8 ratio. Furthermore, the proportion of the CD4+ Leu8+ subpopulation, which identifies inducers of suppression, was significantly reduced. Thus, the decrease in the proportion of suppressor-inducer subsets of PBM might be at least partially, responsible for the augmented generation of LAK cells after mitomycin C administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Akiyoshi T, Arinaga S, Tsuji H (1987) Augmentation of the generation of cell-mediated cytotoxicity in culture by mitomycin C. Cancer Immunol Immunother 24:256–262

    Google Scholar 

  2. Arinaga S, Akiyoshi T, Tsuji H (1986) Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients. Cancer Res 46:4213–4216

    Google Scholar 

  3. Ben-Efrain S, Komlos L, Notmann J, Hart J, Halbrecht I (1985) In vitro selective effect of melphalan on human T-cell populations. Cancer Immunol Immunother 19:53–57

    Google Scholar 

  4. Berd D, Maguire HC, Mastrangelo MJ (1984) Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res 44:1375–1380

    Google Scholar 

  5. Berd D, Mastrangelo MJ (1988) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res 48:1671–1675

    Google Scholar 

  6. Damle NK, Mohagheghpour N, Engleman EG (1984) Soluble antigen-primed inducer T cells activate antigen-specific suppressor T cells in the absence of antigen-pulsed accessory cells: phenotype definition of suppressor-inducer and suppressor-effector cells. J Immunol 132:644–650

    Google Scholar 

  7. Damle NK, Doyle LV, Bradley EC (1986) Interleukin 2-activated human killer cells are derived from phenotypically heterogenous precursors. J Immunol 137:2814–2822

    Google Scholar 

  8. Ehrke MJ, Tomazic V, Ryoyama K, Cohen SA, Mihich E (1983) Adriamycin induced immunomodulation: dependence upon time of administration. Int J Immunopharmacol 5:43–48

    Google Scholar 

  9. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841

    Article  CAS  PubMed  Google Scholar 

  10. Grimm EA, Vose BM, Chu EW, Wilson DJ, Lotze MT, Rayner AA, Rosenberg SA (1984) The human mixed lymphocyteumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissues. Cancer Immunol Immunother 17:83–89

    Google Scholar 

  11. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA (1985) Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 157:884–897

    Google Scholar 

  12. Hinuma S, Onda H, Naruo K, Ichimori Y, Koyama M, Tsukamoto K (1982) Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes. Biochem Biophys Res Commun 109:363–369

    Google Scholar 

  13. Itoh K, Tilen AB, Kumagai K, Balch DM (1985) Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. J Immunol 134:802–807

    Google Scholar 

  14. Landy A, Gartland GL, Clement LT (1983) Characterization of phenotypically distinct subpopulation of Leu-2+ cells that suppresses T cell proliferative responses. J Immunol 131:2757–2761

    Google Scholar 

  15. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA 256:3117–3124

    Article  CAS  PubMed  Google Scholar 

  16. Ogura T, Shindo H, Shinzato O, Namba M, Masuno T, Inoue T, Kishimoto S, Yamamura Y (1982) In vitro tumor cell killing by peritoneal macrophages from mitomycin C-treated rats. Cancer Immunol Immunother 13:112–117

    Google Scholar 

  17. Orsini F, Pavelic Z, Mihich E (1977) Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res 37:1719–1726

    Google Scholar 

  18. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492

    CAS  PubMed  Google Scholar 

  19. Rosenberg SA, Lotze M, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897

    CAS  PubMed  Google Scholar 

  20. Shindo H, Ogura T, Masuno T, Hayashi S, Kishimoto S (1985) Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice. Cancer Immunol Immunother 20:145–150

    Google Scholar 

  21. Stephan HI, Rittershaus CW, Healey KW, Struzziero CC, Hoffman RA, Hansen PW (1982) Rapid enumeration of T lymphocytes by a flow-cytometric immunofluorescence method. Clin Chem 28:1905–1910

    Google Scholar 

  22. Ting CC, Yang SS, Hargrove ME (1984) Induction of suppressor T-cells by interleukin 2. J Immunol 133:261–266

    Google Scholar 

  23. Ting CC, Yang SS, Hargrove ME (1986) Lymphokine-induced cytotoxicity: characterization of effectors, precursors, and regulatory ancillary cells. Cancer Res 46:513–518

    Google Scholar 

  24. Tomazic V, Ehrke MJ, Mihich E (1981) Augmentation of the development of immune responses of mice against allogeneic tumor cells after adriamycin treatment. Cancer Res 41:3370–3376

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Medical Institute of Bioregulation, Kyushu University 69, 874, Beppu, Japan

    Shigeru Nanbara, Shinya Arinaga & Tsuyoshi Akiyoshi

Authors
  1. Shigeru Nanbara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinya Arinaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tsuyoshi Akiyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nanbara, S., Arinaga, S. & Akiyoshi, T. Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients. Cancer Immunol Immunother 29, 237–241 (1989). https://doi.org/10.1007/BF00199210

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00199210

Keywords

Search

Navigation